The landscape of obesity treatment is quickly changing — and with its acquisition this week of Apollo Endosurgery, medical device maker Boston Scientific is again shaking up the space.
“We’ve been calling it a measured entry into the bariatric space,” said Brian Dunkin, who oversees the medical affairs of Boston Scientific’s endoscopy division. “We want to get our experience using a technology that has clinical data to support its use.”
For decades, Boston Scientific’s core focus has been on minimally invasive surgery; it sells devices to treat cardiological, urological, and neurological disease. In 2022, nearly one-fifth of the company’s sales were from devices used in endoscopies, a less-invasive procedure used to look inside the body.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect